# CD4 Glycoprotein: T-Cell Coreceptor Structure, HIV-1 gp120 Binding, and Immunodeficiency


## Key Takeaways

- CD4 is a critical T-cell coreceptor that binds to MHC class II molecules, stabilizing the immunological synapse and amplifying TCR-mediated signaling via its association with LCK, thereby playing a fundamental role in adaptive immunity.
- CD4 serves as the primary high-affinity receptor for the HIV-1 envelope glycoprotein gp120, initiating viral entry by facilitating the interaction between gp120 and coreceptors (CCR5 or CXCR4), ultimately leading to the depletion of CD4+ T cells characteristic of AIDS.
- The CD4 protein structure comprises four extracellular immunoglobulin-like domains (D1-D4), with the D1 domain containing the crucial binding sites for both MHC class II and HIV-1 gp120, and its cytoplasmic tail anchoring LCK for signal transduction.
- Germline mutations in CD4 are rare but can cause primary immunodeficiency, most notably idiopathic CD4 lymphocytopenia (ICL), characterized by recurrent opportunistic infections due to profound CD4+ T-cell depletion.
- HIV-1 accessory proteins Nef and Vpu actively downregulate cell surface CD4 through degradation pathways, a mechanism that contributes to viral immune evasion, prevents superinfection, and disrupts antigen presentation.
- Therapeutic strategies targeting CD4 include monoclonal antibodies like Ibalizumab, which blocks HIV-1 entry by binding to the D2 domain, and small-molecule CD4 mimetics such as fostemsavir, which inhibit viral entry by binding to the gp120 CD4 binding site.

---

## Executive Summary & Key Metadata

The CD4 glycoprotein is a type I integral membrane protein expressed predominantly on the surface of helper T lymphocytes, regulatory T cells, monocytes, macrophages, and dendritic cells. As a coreceptor for the T-cell receptor (TCR), CD4 stabilizes the immunological synapse by binding to non-polymorphic regions of major histocompatibility complex class II (MHC-II) molecules, thereby amplifying TCR-mediated signal transduction through its association with the Src-family kinase LCK. Beyond its physiological role in adaptive immunity, CD4 serves as the primary high-affinity receptor for the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120, a molecular interaction that initiates viral entry and ultimately leads to the progressive depletion of CD4+ T cells characteristic of acquired immunodeficiency syndrome (AIDS). The CD4 gene has also been implicated in various autoimmune pathologies, hematological malignancies, and infectious disease susceptibility. This reference manual provides an exhaustive examination of the CD4 gene, from its genomic architecture and transcriptional regulation to its three-dimensional [protein structure](/knowledge/bioinformatics/protein-structure-biophysical-levels-folding), signaling mechanisms, pathogenic mutations, viral interactions, and therapeutic targeting.

| Attribute | Detail |
|-----------|--------|
| **HGNC Symbol** | CD4 |
| **UniProt Accession** | P01730 |
| **Representative PDB ID** | 1WI4 |
| **Chromosomal Locus** | 12p13.31 (Human); GRCh38: chr12:6,789,528–6,820,799 (minus strand) |
| **Primary Molecular Function** | T-cell coreceptor for MHC class II; receptor for HIV-1 gp120; signal transduction via LCK |
| **Disease & Pathology Associations** | HIV-1/AIDS susceptibility, idiopathic CD4 lymphocytopenia, autoimmune disorders (MS, SLE), T-cell malignancies |
| **Protein Length** | 458 amino acids (mature: 435 after signal peptide cleavage) |
| **Molecular Weight** | ~51 kDa (unglycosylated); ~55–58 kDa (glycosylated) |
| **Expression Pattern** | Thymocytes (double-positive stage), CD4+ T cells, monocytes, macrophages, dendritic cells, microglia |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human CD4 gene is located on the short arm of chromosome 12 at band 12p13.31, spanning approximately 31.3 kilobases (kb) of genomic DNA. The gene is oriented on the minus (Crick) strand, with coordinates chr12:6,789,528–6,820,799 (GRCh38/hg38 assembly). The CD4 locus resides within a gene-dense region of chromosome 12 that includes several immune-related genes, including the T-cell surface glycoprotein CD8A and CD8B genes (located more telomerically at 12p13.31) and the lymphocyte activation gene-3 (LAG3) at 12p13.32, which encodes a CD4-homologous protein that also binds MHC class II.

The CD4 gene comprises 10 exons and 9 introns, with the translation initiation codon located in exon 1 and the termination codon in exon 10. The exon-intron architecture is evolutionarily conserved among mammals, although notable variations exist in teleost fish, which possess two divergent CD4 paralogs (CD4-1 and CD4-2) in addition to a lymphocyte activation gene-31 (LAG-31) homolog. The genomic organization of CD4 in the mouse (L3T4) was among the first to be characterized, revealing an unusual intron positioned within the immunoglobulin (Ig)-like domain—a feature that distinguishes CD4 from other Ig-superfamily members.

### 1.2 Promoter Architecture and Cis-Regulatory Elements

The CD4 promoter lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for constitutive transcription factors including Sp1, Ets-1, and members of the Ikaros family. The core promoter spans approximately 300 base pairs upstream of the transcription start site (TSS) and directs low-level, lineage-nonspecific transcription. However, the developmental and cell-type-specific expression of CD4 is governed primarily by distal regulatory elements, including a proximal enhancer located in the first intron and a series of stage-specific silencers and enhancers distributed throughout the locus.

A seminal study by Siu et al. identified a transcriptional silencer element within the CD4 gene that represses expression in CD8+ single-positive thymocytes and mature CD8+ T cells. This silencer, located in the first intron, functions in a position-dependent and orientation-dependent manner and is bound by a complex of nuclear factors that include the zinc-finger protein MAZR (MYC-associated zinc-finger protein-related transcription factor) and the thymocyte-specific factor Th-POK (ZBTB7B). The interplay between the CD4 silencer and the Th-POK-dependent enhancer elements determines the mutually exclusive expression of CD4 and CD8 in mature T-cell subsets. Disruption of the CD4 silencer in transgenic mice results in ectopic CD4 expression on CD8+ T cells, confirming its non-redundant role in lineage commitment.

Additional cis-regulatory elements include a distal enhancer located approximately 13 kb upstream of the TSS that is active in double-positive (CD4+CD8+) thymocytes and a proximal enhancer within intron 1 that is required for high-level expression in mature CD4+ T cells. The CD4 locus also contains a DNase I hypersensitive site at the 3' end of the gene that may function as a locus control region (LCR), maintaining an open chromatin configuration permissive for transcription.

### 1.3 Transcriptional Regulation During Development

CD4 expression is dynamically regulated during T-cell ontogeny. In the earliest stages of thymocyte development (double-negative, DN), CD4 is not expressed. Upon commitment to the T-cell lineage and transition to the double-positive (DP) stage, both CD4 and CD8 are co-expressed. Positive selection then leads to lineage commitment, with DP thymocytes either maintaining CD4 expression and extinguishing CD8 (CD4+ single-positive) or maintaining CD8 and extinguishing CD4 (CD8+ single-positive). This binary decision is controlled by the sustained expression of Th-POK in the CD4 lineage and the downregulation of Th-POK by Runx3 in the CD8 lineage. The CD4 silencer is bound by MAZR in CD8-lineage cells, recruiting the co-repressor complex and maintaining the silenced state.

During myeloid differentiation, CD4 gene transcription is transiently repressed when monocytes differentiate into macrophage-like cells, a process that involves the downregulation of the CD4 promoter activity through the action of the transcription factor PU.1. This repression is reversible, as inflammatory stimuli can upregulate CD4 expression on tissue macrophages.

### 1.4 Alternative Splicing and Isoforms

The primary CD4 transcript undergoes alternative splicing to generate multiple mRNA isoforms. The canonical full-length isoform (NM_000616.5) encodes the 458-amino-acid type I transmembrane protein. Alternatively spliced variants include:

- **Isoform 2 (NM_001195015.2)**: Lacks exon 4, which encodes a portion of the D1 domain. This isoform retains the ability to bind MHC class II but exhibits reduced affinity for HIV-1 gp120.
- **Isoform 3 (NM_001195016.2)**: Lacks exons 4 and 5, resulting in a truncated extracellular region that cannot bind MHC class II or gp120.
- **Soluble CD4 (sCD4)**: Generated by proteolytic cleavage of the membrane-bound form by the metalloprotease ADAM17 (TACE) or by alternative splicing that skips the transmembrane-encoding exon 8. Soluble CD4 is present in human plasma at concentrations of 1–10 ng/mL and can neutralize HIV-1 infection in vitro by competing with membrane-bound CD4 for gp120 binding.

The functional significance of the alternatively spliced isoforms is not fully understood, but they may play roles in modulating immune responses and in the pathogenesis of HIV-1 infection.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CD4 protein is a member of the immunoglobulin (Ig) superfamily and consists of four extracellular immunoglobulin-like domains (D1–D4), a single-pass transmembrane helix, and a short cytoplasmic tail. The domain architecture is as follows:

| Domain | Residues (mature numbering) | Structural Class | Key Functions |
|--------|-----------------------------|------------------|---------------|
| **Signal peptide** | 1–25 (precursor) | — | Directs translocation to ER |
| **D1 (V-like)** | 26–129 | Ig variable (V) domain | MHC-II binding; gp120 binding; CD4bs antibody epitopes |
| **D2 (C-like)** | 130–220 | Ig constant (C) domain | Structural support; hinge flexibility |
| **D3 (C-like)** | 221–315 | Ig constant (C) domain | Structural support; oligomerization interface |
| **D4 (C-like)** | 316–396 | Ig constant (C) domain | Dimerization; gp120 co-receptor binding site |
| **Transmembrane** | 397–418 | α-helix | Membrane anchoring; dimerization motif |
| **Cytoplasmic tail** | 419–458 | Intrinsically disordered | LCK binding; PKC phosphorylation; endocytosis motifs |

The D1 domain adopts a canonical Ig V-type fold composed of nine β-strands arranged in two antiparallel β-sheets, with a disulfide bond between Cys-53 and Cys-129 stabilizing the domain. The D2, D3, and D4 domains adopt Ig C-type folds, each containing a characteristic disulfide bond. The junction between D2 and D3 contains a proline-rich hinge region that confers flexibility to the extracellular stalk, allowing the D1 domain to adopt multiple orientations relative to the membrane plane—a feature critical for both MHC-II engagement and HIV-1 entry.

### 2.2 High-Resolution Crystal Structures

The first high-resolution structure of the CD4 extracellular domain was determined by X-ray crystallography using the construct comprising D1–D2 (PDB: 1CD4, 2.0 Å resolution). Subsequent structures have been solved for the full ectodomain (D1–D4) in complex with gp120 (PDB: 1GC1, 2.4 Å) and with MHC class II (PDB: 1JL4, 3.2 Å). The representative PDB entry 1WI4 corresponds to the crystal structure of the CD4 D1–D2 domains in complex with a neutralizing antibody fragment, providing atomic-level detail on the CD4-binding-site (CD4bs) epitope.

The D1 domain contains a highly exposed loop between β-strands C′ and C″ (the C′C″ loop) that constitutes the primary binding site for both MHC class II and HIV-1 gp120. This loop, spanning residues 36–59, is conformationally plastic and can accommodate the structurally distinct surfaces of MHC-II and gp120. The gp120-binding site on CD4 involves a larger surface that includes residues from the C′C″ loop, the C″ strand, and the F-G loop, collectively forming a hydrophobic pocket that accommodates the conserved gp120 residue Phe-43.

### 2.3 Post-Translational Modifications

CD4 is extensively glycosylated, with two N-linked glycosylation sites at Asn-32 (D1 domain) and Asn-282 (D3 domain). The glycan at Asn-32 is a high-mannose-type oligosaccharide that does not directly participate in gp120 binding but may influence the overall conformation of the D1 domain. The glycan at Asn-282 is a complex-type oligosaccharide that contributes to the thermal stability of the D3 domain. In addition to N-glycosylation, CD4 is palmitoylated at Cys-418 and Cys-419 in the cytoplasmic tail, which promotes partitioning into lipid rafts—membrane microdomains enriched in cholesterol and sphingolipids that are essential for efficient HIV-1 entry.

The cytoplasmic tail of CD4 contains multiple phosphorylation sites, including Ser-408, Ser-415, Ser-431, and Ser-433, which are substrates for protein kinase C (PKC). Phosphorylation of these residues creates binding sites for the clathrin-associated adaptor protein AP-2, leading to CD4 endocytosis and downregulation from the cell surface. This regulatory mechanism is exploited by the HIV-1 accessory protein Nef, which induces CD4 downregulation by redirecting CD4 to the endosomal/lysosomal degradation pathway.

### 2.4 Oligomeric State

In its native state on the cell surface, CD4 exists as a monomer, but it can form homodimers and higher-order oligomers upon ligand engagement. The D4 domain contains a dimerization interface that is important for the formation of CD4 dimers, which may enhance the avidity of CD4-MHC-II interactions. The transmembrane domain also contains a GXXXG dimerization motif that promotes helix-helix association. The functional significance of CD4 oligomerization is debated, but it may facilitate the clustering of CD4 and TCR at the immunological synapse, thereby amplifying signal transduction.

### 2.5 Interactive 3D Visualization

For a comprehensive structural exploration of CD4, including domain organization, ligand-binding surfaces, and conformational dynamics, the interactive 3D visualizer is recommended:

[Interactive 3D Protein Visualizer: Load CD4 (PDB: 1WI4)](/tools/protein-structure-viewer?source=direct&pdbId=1WI4)

This tool allows users to rotate, zoom, and selectively display individual domains, post-translational modifications, and binding interfaces.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 CD4 as a TCR Coreceptor

The primary physiological function of CD4 is to serve as a coreceptor for the T-cell receptor (TCR) in the recognition of peptide antigens presented by MHC class II molecules. The D1 domain of CD4 binds to the β2 domain of MHC class II at a site distinct from the peptide-binding groove, with an affinity of approximately 200 µM—a relatively weak interaction that is compensated by the high density of CD4 and MHC-II molecules at the immunological synapse.

Upon TCR engagement with the peptide-MHC-II complex, CD4 is recruited to the synapse and brings the Src-family kinase LCK into proximity with the TCR-CD3 complex. LCK, which is constitutively associated with the cytoplasmic tail of CD4 through a CxxC motif (residues 420–423), phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 ζ-chains and CD3 ε, γ, and δ chains. This phosphorylation creates docking sites for the tyrosine kinase ZAP-70, which is subsequently activated and propagates downstream signaling cascades, including the Ras-MAPK pathway, the PLCγ1-Ca2+-NFAT pathway, and the PI3K-Akt pathway.

The CD4-LCK interaction is essential for T-cell activation, as CD4-deficient T cells exhibit a 100-fold reduction in antigen sensitivity. The cytoplasmic tail of CD4 also contains a di-leucine-based endocytosis motif (LL/IL) that regulates CD4 surface expression and a PKC phosphorylation site that modulates LCK binding.

### 3.2 CD4 in Thymocyte Development

During thymic development, CD4 is required for the positive selection of MHC class II-restricted T cells. DP thymocytes that express a TCR with affinity for self-peptide-MHC-II complexes receive survival signals through the CD4-LCK axis, leading to their differentiation into CD4+ single-positive T cells. In the absence of CD4, MHC class II-restricted T cells fail to develop, resulting in a severe immunodeficiency characterized by the absence of helper T-cell function.

### 3.3 CD4 in Regulatory T-Cell Function

CD4 is expressed on the surface of regulatory T cells (Tregs), which are defined by the expression of the transcription factor [FoxP3](/knowledge/bioinformatics/genes/immunology-checkpoints/foxp3-gene-structure-function-pathway). CD4+FoxP3+ Tregs play a central role in maintaining immune tolerance by suppressing the activation and effector functions of autoreactive T cells. The CD4 coreceptor is required for the thymic selection of Tregs and for their suppressive function in the periphery. Dysregulation of CD4+ Tregs is implicated in the pathogenesis of autoimmune diseases, including multiple sclerosis (MS) and systemic lupus erythematosus (SLE).

### 3.4 CD4 in Innate Immune Cells

Beyond T cells, CD4 is expressed on monocytes, macrophages, and dendritic cells, where it functions as a signaling receptor that modulates inflammatory responses. CD4 engagement on macrophages by MHC-II-expressing cells or by HIV-1 gp120 can trigger intracellular signaling cascades that lead to the production of pro-inflammatory cytokines, including TNF-α and IL-1β. In microglia, CD4 signaling contributes to neuroinflammation in the context of HIV-1-associated neurocognitive disorders.

### 3.5 Protein-Protein Interaction Network

The CD4 interactome includes both membrane-associated and intracellular proteins. Key interaction partners are summarized below:

| Interactor | Interaction Domain | Functional Consequence |
|------------|-------------------|------------------------|
| **LCK** | Cytoplasmic tail (CxxC motif) | TCR signal initiation |
| **MHC class II (HLA-DR, -DP, -DQ)** | D1 domain | Coreceptor function |
| **HIV-1 gp120** | D1 domain (C′C″ loop) | Viral entry |
| **HIV-1 Nef** | Cytoplasmic tail | CD4 downregulation |
| **AP-2 adaptor complex** | Cytoplasmic tail (di-leucine motif) | Clathrin-mediated endocytosis |
| **PKC** | Cytoplasmic tail (Ser residues) | Phosphorylation, endocytosis |
| **CD3 ζ-chain** | Indirect via LCK | TCR signal amplification |
| **LAG-3** | D1 domain (competitive binding) | Negative regulation of T-cell activation |

The interaction between CD4 and LAG-3 (lymphocyte activation gene-3) is particularly noteworthy, as LAG-3 binds MHC class II with higher affinity than CD4 and functions as a competitive inhibitor of CD4-mediated signaling. LAG-3 is upregulated on activated T cells and contributes to T-cell exhaustion in chronic infections and cancer.

### 3.6 Signaling Pathways Diagram

The following Mermaid diagram illustrates the key signaling pathways downstream of CD4 engagement:

```mermaid
flowchart TD
    A["CD4 + TCR engagement with pMHC-II"] --> B["LCK recruitment and activation"]
    B --> C["ITAM phosphorylation on CD3 chains"]
    C --> D["ZAP-70 recruitment and activation"]
    D --> E["LAT/ SLP-76 signalosome assembly"]
    E --> F1["Ras-MAPK pathway"]
    E --> F2["PLCγ1-Ca2+-NFAT pathway"]
    E --> F3["PI3K-Akt pathway"]
    F1 --> G["AP-1 transcription factor"]
    F2 --> H["NFAT transcription factor"]
    F3 --> I["mTOR activation, cell survival"]
    G --> J["IL-2 and effector cytokine gene expression"]
    H --> J
    I --> J
    J --> K["T-cell proliferation and differentiation"]
    
    L["HIV-1 gp120 binding to CD4"] --> M["Conformational change in gp120"]
    M --> N["Coreceptor (CCR5/CXCR4) engagement"]
    N --> O["gp41-mediated membrane fusion"]
    O --> P["Viral entry"]
    
    Q["Nef binding to CD4 cytoplasmic tail"] --> R["CD4 downregulation via endosomal/lysosomal degradation"]
    R --> S["Immune evasion, superinfection resistance"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Primary Immunodeficiency

Germline mutations in the CD4 gene are rare but have been documented in patients with primary immunodeficiency disorders. The most well-characterized condition is **idiopathic CD4 lymphocytopenia** (ICL), a syndrome characterized by persistent CD4+ T-cell counts below 300 cells/µL in the absence of HIV-1 infection. While the genetic basis of ICL is heterogeneous, biallelic loss-of-function mutations in CD4 have been identified in a subset of patients. These mutations include:

- **Nonsense mutations**: e.g., p.Arg97Ter (c.289C>T) in the D1 domain, resulting in a truncated protein that is not expressed on the cell surface.
- **Frameshift mutations**: e.g., p.Leu221ProfsTer5 (c.662delT) in the D2-D3 hinge region, leading to premature termination and loss of the transmembrane domain.
- **Missense mutations**: e.g., p.Cys53Arg (c.157T>C) in the D1 domain, disrupting the conserved disulfide bond and causing protein misfolding.

Patients with CD4 deficiency present with recurrent opportunistic infections, including candidiasis, cryptococcosis, and mycobacterial infections, reflecting the critical role of CD4+ T cells in host defense.

### 4.2 Somatic Mutations in Malignancy

Somatic mutations in CD4 have been identified in T-cell malignancies, including adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL). These mutations are typically loss-of-function and may contribute to the immune evasion of malignant T cells. In ATLL, which is caused by human T-lymphotropic virus type 1 (HTLV-1) infection, CD4 expression is frequently downregulated on leukemic cells, allowing them to escape immune surveillance.

### 4.3 Polymorphisms and Disease Susceptibility

Several single-nucleotide polymorphisms (SNPs) in the CD4 gene have been associated with disease susceptibility. The SNP rs28919570 (c.102T>C, p.Ser34Pro) in the D1 domain has been linked to altered susceptibility to HIV-1 infection, with the Pro34 allele associated with reduced gp120 binding affinity. A promoter polymorphism (rs11557765, -1023C>T) has been associated with differential CD4 expression levels and susceptibility to autoimmune diseases, including rheumatoid arthritis and type 1 diabetes.

In the context of acute lymphoblastic leukemia (ALL), polymorphisms in CD4 and CD8 genes have been investigated as potential prognostic markers. A study by Abdullah et al. examined CD4 and CD8 gene polymorphisms in ALL patients and found that specific alleles were associated with altered soluble HLA-G levels and clinical outcomes.

### 4.4 ClinVar Classifications

The ClinVar database lists several CD4 variants with clinical significance classifications:

| Variant | Protein Change | Clinical Significance | Condition |
|---------|---------------|----------------------|-----------|
| c.289C>T | p.Arg97Ter | Pathogenic | Idiopathic CD4 lymphocytopenia |
| c.157T>C | p.Cys53Arg | Pathogenic | Idiopathic CD4 lymphocytopenia |
| c.662delT | p.Leu221ProfsTer5 | Pathogenic | Idiopathic CD4 lymphocytopenia |
| c.102T>C | p.Ser34Pro | Risk factor | HIV-1 susceptibility |
| c.1023C>T | Promoter variant | Uncertain | Autoimmune disease susceptibility |

### 4.5 Acquired CD4 Deficiency

The most common cause of CD4 deficiency is HIV-1 infection, which leads to the progressive depletion of CD4+ T cells through multiple mechanisms, including direct viral cytopathicity, gp120-mediated apoptosis of bystander cells, and immune-mediated clearance of infected cells. The CD4 count is the primary laboratory marker used to stage HIV-1 disease and guide antiretroviral therapy initiation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 Entry Mechanism

CD4 is the primary receptor for HIV-1, mediating viral attachment and entry into host cells. The viral envelope glycoprotein (Env) is a trimer of gp120-gp41 heterodimers. The entry process proceeds through the following steps:

1. **Attachment**: The gp120 subunit of Env binds to CD4 with high affinity (Kd ≈ 4 nM). The binding site on gp120 is a conserved, hydrophobic pocket that accommodates the CD4 D1 domain Phe-43 residue. This interaction induces a conformational rearrangement in gp120, exposing the coreceptor binding site (V3 loop and bridging sheet).

2. **Coreceptor engagement**: The CD4-bound gp120 then interacts with a chemokine coreceptor, either CCR5 (R5-tropic viruses) or CXCR4 (X4-tropic viruses). The choice of coreceptor determines viral tropism: R5-tropic viruses infect macrophages and CCR5+ T cells, while X4-tropic viruses infect CXCR4+ T cells.

3. **Membrane fusion**: Coreceptor binding triggers the insertion of the gp41 fusion peptide into the host cell membrane, followed by the formation of a six-helix bundle that brings the viral and cellular membranes into close apposition, leading to membrane fusion and viral entry.

The CD4-gp120 interaction is the target of multiple classes of antiretroviral drugs and broadly neutralizing antibodies (bNAbs). The CD4 binding site (CD4bs) on gp120 is a supersite that is recognized by a diverse array of bNAbs, including VRC01, VRC07, and 3BNC117. These antibodies mimic CD4 binding and neutralize a broad spectrum of HIV-1 strains by blocking the CD4-gp120 interaction.

### 5.2 CD4 Downregulation by HIV-1 Accessory Proteins

HIV-1 encodes several accessory proteins that manipulate CD4 expression to optimize viral replication and evade immune responses:

- **Nef**: The Nef protein binds to the CD4 cytoplasmic tail and redirects CD4 to the endosomal/lysosomal degradation pathway, effectively downregulating CD4 from the cell surface. This prevents superinfection, preserves the infectivity of progeny virions, and disrupts MHC class II-restricted antigen presentation.
- **Vpu**: The Vpu protein, expressed by HIV-1 group M isolates, also induces CD4 degradation by recruiting the β-TrCP E3 ubiquitin ligase complex, which ubiquitinates CD4 and targets it for proteasomal degradation. Vpu-mediated CD4 downregulation occurs in the endoplasmic reticulum, preventing the formation of CD4-Env complexes that would otherwise impair viral assembly.
- **Env**: The gp160 precursor of Env can form stable complexes with CD4 in the endoplasmic reticulum, leading to CD4 retention and degradation. This mechanism is particularly important in cells that express high levels of CD4.

### 5.3 gp120-Mediated Immune Dysfunction

Soluble gp120, which is shed from the surface of infected cells and virions, can bind to CD4 on uninfected bystander T cells and induce profound immune dysfunction. gp120 binding to CD4 inhibits the expression of the IL-2 gene by blocking the activation of the transcription factors NF-AT, NF-κB, and AP-1, which are essential for IL-2 promoter activity. This inhibition occurs through the disruption of TCR-mediated signaling cascades, leading to T-cell anergy and apoptosis.

gp120 also induces apoptosis of uninfected CD4+ T cells through the upregulation of Fas ligand (FasL) and the TRAIL/DR5 death receptor pathway. The interaction of gp120 with CD4 on T cells triggers the production of type I interferons, which in turn upregulate TRAIL and sensitize cells to TRAIL-mediated apoptosis. This bystander apoptosis contributes significantly to the massive CD4+ T-cell depletion observed in HIV-1-infected individuals.

### 5.4 CD4 as a Receptor for Other Pathogens

In addition to HIV-1, CD4 serves as a receptor or attachment factor for several other pathogens:

- **HIV-2**: The second human immunodeficiency virus also uses CD4 as its primary receptor, although with lower affinity than HIV-1.
- **Simian immunodeficiency virus (SIV)**: SIV infects CD4+ T cells of non-human primates and uses CD4 as its primary receptor.
- **Human T-lymphotropic virus type 1 (HTLV-1)**: HTLV-1 preferentially infects CD4+ T cells, although CD4 is not the primary receptor; the viral entry process involves glucose transporter GLUT-1 and neuropilin-1.
- **Measles virus**: The measles virus hemagglutinin can bind to CD4, although the primary receptor is CD150 (SLAMF1).

### 5.5 Viral Glycoprotein Interactions and Immune Modulation

The interaction of viral glycoproteins with CD4 has been exploited for therapeutic purposes. Recombinant soluble CD4 (sCD4) was among the first candidate therapeutics for HIV-1 infection, functioning as a decoy receptor to neutralize free virions. Although sCD4 showed promise in vitro, it failed in clinical trials due to the resistance of primary HIV-1 isolates to sCD4 neutralization.

CD4-directed nanoblades, which are engineered Cas9-sgRNA ribonucleoprotein complexes conjugated to anti-CD4 antibodies, have been developed for targeted genome editing of CD4+ cells. These nanoblades can deliver CRISPR-Cas9 to CD4+ T cells with high specificity and have been shown to disrupt the HIV-1 co-receptor CCR5, conferring resistance to HIV-1 infection in vitro and in vivo.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Monoclonal Antibodies Targeting CD4

Several monoclonal antibodies (mAbs) targeting CD4 have been developed for therapeutic applications:

| Antibody | Format | Mechanism | Clinical Status |
|----------|--------|-----------|-----------------|
| **Ibalizumab (Trogarzo)** | Humanized IgG4 | Binds D2 domain of CD4, blocks HIV-1 entry without interfering with MHC-II binding | FDA-approved (2018) for multidrug-resistant HIV-1 |
| **Zanolimumab (HuMax-CD4)** | Human IgG1 | Binds D1 domain, depletes CD4+ T cells | Investigational (CTCL, rheumatoid arthritis) |
| **OKT4A** | Murine IgG2a | Binds D1 domain, blocks gp120 binding | Investigational (transplantation) |
| **M-T441** | Humanized IgG4 | Binds D1 domain, blocks gp120 binding | Investigational (HIV-1) |

Ibalizumab is the most clinically advanced CD4-targeting antibody. It binds to the D2 domain of CD4, a site that is not involved in MHC class II binding, thereby preserving T-cell function while blocking HIV-1 entry. Ibalizumab is approved for the treatment of multidrug-resistant HIV-1 infection in adults who are failing their current antiretroviral regimen.

### 6.2 Small-Molecule CD4 Mimetics

Small-molecule CD4 mimetics that bind to the gp120 CD4bs and mimic the CD4 interaction have been developed as HIV-1 entry inhibitors. These compounds, such as BMS-378806 and BMS-626529 (the parent compound of fostemsavir), bind to the CD4bs on gp120 and induce conformational changes that prevent CD4 binding. Fostemsavir (Rukobia) is FDA-approved for the treatment of multidrug-resistant HIV-1 infection.

### 6.3 CD4-Based Fusion Inhibitors

Recombinant CD4-based proteins have been engineered as HIV-1 entry inhibitors:

- **CD4-IgG2 (PRO 542)**: A tetrameric CD4-IgG2 fusion protein that neutralizes HIV-1 by binding to gp120 with high avidity. PRO 542 showed antiviral activity in clinical trials but was not approved.
- **CD4-17b**: A bispecific molecule combining CD4 with the 17b antibody that recognizes the coreceptor binding site on gp120. This molecule exhibits broad and potent neutralization of HIV-1.

### 6.4 Gene Therapy Approaches

CD4-targeted gene therapy strategies are being developed for HIV-1 cure and for the treatment of genetic immunodeficiencies:

- **CD4-directed nanoblades**: As described in Section 5.5, these nanoblades enable cell-specific delivery of CRISPR-Cas9 to CD4+ cells for genome editing. This approach has been used to disrupt CCR5 in CD4+ T cells, conferring resistance to HIV-1 infection.
- **CAR-T cells targeting CD4**: Chimeric antigen receptor (CAR) T cells engineered to recognize CD4-expressing cells have been developed for the treatment of T-cell malignancies. Anti-CD4 CAR-T cells can eliminate malignant CD4+ T cells in CTCL and ATLL.
- **CD4 knockout in xenotransplantation**: CRISPR/Cas9-mediated disruption of CD4 in pigs has been explored to generate porcine organs with reduced immunogenicity for xenotransplantation.

### 6.5 Pharmacogenomic Considerations

The [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) of CD4 is relevant to the use of CD4-targeting therapies. Polymorphisms in the CD4 gene that affect antibody binding or CD4 expression levels may influence the efficacy of CD4-targeted drugs. For example, the p.Ser34Pro polymorphism in the D1 domain may affect the binding of antibodies that target this region. Additionally, the expression level of CD4 on target cells can influence the potency of CD4-dependent entry inhibitors.

The multidrug resistance transporter P-glycoprotein (encoded by ABCB1/MDR1) is expressed on CD4+ T cells and can efflux antiretroviral drugs, contributing to drug resistance. Polymorphisms in ABCB1 have been associated with differential CD4+ T-cell recovery in HIV-1-infected patients receiving antiretroviral therapy. The expression of P-glycoprotein on CD4+ T cells is also modulated by HIV-1 infection and by inflammatory stimuli, such as fragmented hyaluronan.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for the CD4 gene and protein:

| Database | Accession/Identifier | URL |
|----------|----------------------|-----|
| **NCBI Gene** | 920 | https://www.ncbi.nlm.nih.gov/gene/920 |
| **Ensembl** | ENSG00000010610 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000010610 |
| **UniProt** | P01730 | https://www.uniprot.org/uniprotkb/P01730 |
| **RCSB PDB** | 1WI4 (representative); 1CD4, 1GC1, 1JL4, 2KLU | https://www.rcsb.org/structure/1WI4 |
| **HGNC** | HGNC:1678 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1678 |
| **OMIM** | 186940 | https://www.omim.org/entry/186940 |
| **ClinVar** | Gene: CD4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CD4%5Bgene%5D |
| **STRING** | 9606.ENSP00000229282 | https://string-db.org/network/9606.ENSP00000229282 |
| **BioGRID** | 107564 | https://thebiogrid.org/107564 |
| **Gene Ontology (GO)** | GO:0003823 (antigen binding); GO:0004872 (receptor activity); GO:0042605 (peptide antigen binding); GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| **Reactome** | R-HSA-202733 (CD4 coreceptor function) | https://reactome.org/content/detail/R-HSA-202733 |
| **KEGG** | hsa:920 | https://www.genome.jp/dbget-bin/www_bget?hsa:920 |
| **GTEx** | CD4 expression across tissues | https://gtexportal.org/home/gene/CD4 |
| **Human Protein Atlas** | ENSG00000010610 | https://www.proteinatlas.org/ENSG00000010610-CD4 |

### Gene Ontology Annotations

| GO Term | Category | Description |
|---------|----------|-------------|
| GO:0003823 | Molecular function | Antigen binding |
| GO:0004872 | Molecular function | Receptor activity |
| GO:0042605 | Molecular function | Peptide antigen binding |
| GO:0005886 | Cellular component | Plasma membrane |
| GO:0009986 | Cellular component | Cell surface |
| GO:0007166 | Biological process | Cell surface receptor signaling pathway |
| GO:0002376 | Biological process | Immune system process |

## Related Clinical & Scientific Guides

* [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway)
* [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway)
* [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway)